Apostatin-1 (Apt-1)

  Cat. No.:  DC39045   Featured
Apostatin-1 (Apt-1)
Chemical Structure
For research use only. We do not sell to patients.
We match the best price and quality on market.
Email:order@dcchemicals.com  sales@dcchemicals.com
We are official vendor of:
  • 20
  • 19
  • 18
  • 17
  • 16
  • 15
  • 14
  • 12
  • 11
  • 10
  • 9
  • 8
  • 13
  • 6
  • 5
  • 4
  • 3
  • 2
  • 1
More than 5000 active chemicals with high quality for research!
Field of application
Apostatin-1 (Apt-1) is a novel TRADD inhibitor.Apostatin-1 inhibits RIPK1-dependent apoptosis (RDA) with IC50 of 1.28 μM and shows no significant off-target activity on 97 kinases in KINOME scan profiling.Inhibition of TRADD by Apostatin-1 blocks apoptosis and restores cellular homeostasis by activating autophagy in cells with accumulated mutant tau, α-synuclein, or huntingtin. Treatment with Apt-1 restored proteostasis and inhibited cell death in a mouse model of proteinopathy induced by mutant tau(P301S).
Cas No.:
Chemical Name: Apostatin-1
Synonyms: Apostatin-1;Apostatin-1;Apostatin-1;APT1;APT 1;APT-1
Formula: C19H27N3Os
M.Wt: 345.502
Purity: >98%
Sotrage: 2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO
Publication: Daichao Xu, Heng Zhao, Minzhi Jin, et al.Modulating TRADD to restore cellular homeostasis and inhibit apoptosis.Nature.Published: 23 September 2020
In Vivo:
In Vitro:
Kinase Assay:
Cell Assay:
Animal Administration:
Cat. No. Product name Field of application
DC39117 Linoleoyl Ethanolamide Linoleoyl ethanolamide is an endocannabinoid detected in porcine brain and murine peritoneal macrophages which contains linoleate in place of the arachidonate moiety of arachidonyl ethanolamide (AEA).
DC39116 ARS-1323-alkyne ARS-1323-alkyne, a switch-II pocket (S-IIP) inhibitor, is a conformational specific chemical reporter of KRASG12C nucleotide state in living cells.
DC39115 LCB-1 protein LCB-1 is a designed antiviral protein inhibiting SARS-CoV-2. LCB1 is roughly six times more potent on a per mass basis than the most effective monoclonal antibodies reported thus far.LCB1 is currently being evaluated in rodents. LCB1 binds the Spike receptor binding domain (RBD) with affinity below 1 nM and blocks ARS-CoV-2 infection of Vero E6 cells with IC50 of 23.54 pM.
DC9711 GSK-3008348 HCl GSK3008348 is an Integrin alphaV inhibitor.
DC39059 MBX2329 MBX2329 is a small molecule inhibitor of influenza virus H1N1 hemagglutinin.
DC39058 MF-438 MF-438 is a potent and orally bioavailable stearoyl-CoA desaturase 1 (SCD1) inhibitor with an EC50 of 2.3 nM for rSCD1[1].
DC39056 DS-1971a DS-1971a is a Potent, Selective NaV1.7 Inhibitor. In preclinical studies, DS-1971a demonstrated highly potent selective in vitro profile with robust efficacy in vivo. DS-1971a exhibited a favorable toxicological profile, which enabled multiple-dose studies of up to 600 mg bid or 400 mg tid (1200 mg/day) administered for 14 days to healthy human males. DS-1971a is expected to exert potent efficacy in patients with peripheral neuropathic pain, with a favorable safety profile.
DC39055 BIIB068 BIIB068 is a potent, selective, reversible and orally active BTK inhibitor. BIIB068 demonstrated good kinome selectivity with good overall drug-like properties for oral dosing, was well tolerated across preclinical species at pharmacologically relevant doses with good ADME properties, and achieved >90% inhibition of BTK phosphorylation (pBTK) in humans.
DC39053 XP-59 XP-59 is a potent inhibitor of the SARS-CoV Mpro, with a Ki of 0.1 μM[1].The SARS-CoV main proteinase (Mpro) plays a central role in the formation of the viral replicase/transcriptase complex and is thus an ideal target for the development of suitable drugs[1].
DC39052 LQZ-7I LQZ-7I is a survivin-targeting inhibitor. LQZ-7I inhibits survivin dimerization. LQZ-7I orally effectively inhibits xenograft tumor growth and induces survivin loss in tumors[1].